A Prospective, Randomized, Open Study on the Efficacy and Safety of the GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Triptorelin (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Immune System Regulation
- 01 Feb 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Oct 2019.
- 20 Sep 2018 According to ISR Immune System Regulation Holding media release, the first patient is now enrolled in this study. The study is expected to be ending in Q2 2019.
- 19 Sep 2018 Planned End Date changed from 1 May 2019 to 1 Nov 2019.